New targeted therapy trial offers hope for Tough-to-Treat lung cancer
NCT ID NCT07308106
Summary
This study is testing an experimental drug called SKB571 for people with advanced non-small cell lung cancer that has a specific genetic change called a MET abnormality. The trial will enroll 60 patients whose cancer has worsened after standard treatments to see if the drug is safe and can shrink or control their tumors. Participants will receive the drug by injection until their cancer progresses or side effects become too difficult.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.